Loading
Aura Biosciences, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 20 May 2025.
Aura Biosciences, Inc.: what insiders have been doing
Aura Biosciences, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Between 18 October 2025 and 18 October 2026, 15 insiders published 30 filings.
The flow runs one way only: 12 sales worth €727k, from 6 insiders, and no purchase. The amount is not disclosed for 1 filing. de los Pinos Elisabet filed the largest sale, €203k, on 17 February 2026.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Across the 5,814 companies tracked on its exchange, the median is 19 filings; at 30 filings, this issuer sits above that mark. The full history, which starts in 2021, counts 13 purchases against 36 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists net income at -106.2 m USD.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
105
Thresholds
n/a
Buy Volume
€29M
13 ops. · all time
Sell Volume
€2M
36 ops. · all time
Who traded when
BuySaleAmy Elazzouzi6 sales
Pinos Elisabet de los5 sales
Janet Jill Hopkins4 sales
Anthony S. Gibney1 buy2 sales
Conor Kilroy3 sales
Mark Plavsic3 sales
+1 other insider
Since the insiders bought
- +28.4%Entry US$5.96 · Close at T+365 US$7.65
- +28.4%Entry US$5.96 · Close at T+365 US$7.65
- +44.9%Entry US$7.69 · Close at T+365 US$11.14
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$6.17
Analyst consensus
5 analysts1.17/5
US$12.00Target US$16.60(+169%)US$23.00
Income statement
EBITDA-US$111.7M
Net income-US$106.2M0.0% margin
Valuation
P/Book2.0x
Beta0.41
Balance sheet & cash
Market capUS$639.9M
Total debtUS$17.4M
Free Cash Flow-US$85.2M
Debt / Equity5%
Profitability & ownership
ROE-53.5%
ROA-31.2%
% insiders2.4%
% institutions95.8%
Last declaration on 1 September 2026
Declarations105 total
134,513 shares0Common StockSEC:0002148701-26-000008:0
107,611 shares0Common StockSEC:0001946505-26-000009:0
58,850 shares0Common StockSEC:0001997710-26-000004:0
23,540 shares0Common StockSEC:0002042910-26-000003:0
100,885 shares0Common StockSEC:0002148785-26-000009:0
30,000 shares0Common StockSEC:0001193125-26-298542:0
14,858 sharesCommon StockSEC:0001193125-26-292685:0
12,824 shares@ US$6.420.011% mcap100.0% of flowCommon StockSEC144:0001193125-26-272705
12,824 sharesCommon StockSEC:0001193125-26-272703:0
15,000 sharesCommon StockSEC:0001193125-26-271165:0
15,000 sharesCommon StockSEC:0001193125-26-271168:0
15,000 sharesCommon StockSEC:0001193125-26-271170:0
15,000 sharesCommon StockSEC:0001193125-26-271171:0
11,738 shares@ US$7.020.0100% mcap44.9% of flowCommon StockSEC:0001193125-26-159579:0
62,339 shares0Common StockSEC:0001193125-26-088170:0
71,245 shares0Common StockSEC:0001193125-26-088168:0
62,339 shares0Common StockSEC:0001193125-26-088158:0
166,000 shares0Common StockSEC:0001193125-26-088162:0
89,056 shares0Common StockSEC:0001193125-26-088154:0
44,528 shares0Common StockSEC:0001193125-26-088150:0
8,549 shares@ US$5.0642.1% of flowCommon StockSEC:0001193125-26-055494:0
12,079 shares@ US$5.0533.0% of flowCommon StockSEC:0001193125-26-055499:0
20,401 shares@ US$5.0630.0% of flowCommon StockSEC:0001193125-26-055496:0
15,890 shares@ US$5.0531.3% of flowCommon StockSEC:0001193125-26-055497:0
47,648 shares@ US$5.0617.5% of flowCommon StockSEC:0001193125-26-055487:0
25 of 105 declarations
About Aura Biosciences, Inc.
Aura Biosciences, Inc. is a U.S.-based clinical-stage biotechnology company listed on the NASDAQ under the ticker AURA. Headquartered in Boston, Massachusetts, and incorporated in Delaware in 2009, Aura is focused on developing a novel class of targeted oncology therapies designed to preserve organ function while treating cancer. That positioning matters in a field where standard-of-care treatments can be highly invasive and may permanently damage healthy tissue, especially in hard-to-treat localized tumors. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001501796/000119312526130401/aura-20251231.htm?utm_source=openai))
The company’s core platform is built around virus-like drug conjugates, or VDCs, a targeted delivery approach intended to concentrate therapeutic activity on tumor cells. Aura’s lead asset is bel-sar, previously referenced as AU-011, which is being developed first in ocular oncology, particularly for choroidal melanoma, a rare and potentially vision- and life-threatening eye cancer. The company is also expanding the platform into additional ophthalmic settings and into urologic oncology, with a notable focus on non-muscle-invasive bladder cancer (NMIBC). This broader pipeline is strategically important because it gives Aura multiple shots on goal beyond a single rare-disease indication. ([aurabiosciences.com](https://www.aurabiosciences.com/pipeline-programs/pipeline/?utm_source=openai))
Read moreShow less
From a competitive standpoint, Aura is differentiated by its precision-oncology strategy aimed at high unmet-need tumors where existing therapies may be destructive or suboptimal. In choroidal melanoma, management has historically relied on radiotherapy approaches that can preserve life but often at a substantial cost to vision. Aura’s value proposition is to potentially shift the treatment paradigm toward a less invasive, organ-preserving option. At the same time, the business remains high risk: Aura is still a clinical-stage company, has no approved products, and has not generated product revenue to date according to its latest SEC filings. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001501796/000119312526130401/aura-20251231.htm?utm_source=openai))
Geographically, Aura is primarily a United States company with clinical and corporate operations centered in Boston and trial activity tied to specialized oncology centers. Recent milestones include continued advancement of the global Phase 3 CoMpass trial in early-stage choroidal melanoma, positive Phase 2 end-of-study data, and the release of full-year 2025 financial results in March 2026. The company has also highlighted formulation progress and the potential to extend bel-sar into non-ocular solid tumors, starting with urologic oncology. For international investors, AURA is best viewed as a differentiated, innovation-led biotech name on the NASDAQ, with meaningful upside tied to clinical execution but also substantial financing and regulatory risk. ([ir.aurabiosciences.com](https://ir.aurabiosciences.com/news-releases/news-release-details/aura-biosciences-reports-fourth-quarter-and-full-year-2025?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
